Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

PD-2 Inhibitors

Chemical inhibitors of PD-2 target various signaling pathways to impede its activity. Palbociclib, as a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, hampers the progression of the cell cycle, which is essential for PD-2 function. The disruption of the normal progression of the cell cycle by Palbociclib consequently leads to an indirect inhibition of PD-2, as PD-2 requires specific cell-cycle stages for its activity. Similarly, Rapamycin, by inhibiting mTOR, suppresses downstream signaling that contributes to PD-2 activity. The mTOR pathway is fundamental for various cellular processes, including those that regulate PD-2 function, and Rapamycin's interference with this pathway demonstrates an indirect method of inhibiting PD-2.

Moreover, LY294002 and Triciribine target the PI3K/Akt signaling pathway, with LY294002 directly inhibiting PI3K and Triciribine targeting Akt, thereby disrupting a critical upstream regulator of PD-2. The resultant decrease in PI3K/Akt signaling can lead to a reduction in PD-2 activity. U0126 and Selumetinib, both MEK inhibitors, and PD98059, which also targets MEK, suppress the MAPK/ERK pathway, another regulator of PD-2. With reduced activity of this pathway, PD-2 activity is diminished. SB203580 and SP600125 inhibit the p38 MAPK and JNK pathways, respectively, both of which are implicated in the regulation of PD-2. Inhibition of these kinase pathways prevents the phosphorylation events that are necessary for full PD-2 activity. Additionally, PP2 and Dasatinib, by inhibiting Src family kinases, and Sunitinib, by inhibiting receptor tyrosine kinases, block signaling routes that are requisite for PD-2's functional state. The inhibition of these kinases by PP2, Dasatinib, and Sunitinib leads to a reduction in PD-2 signaling, thereby providing further methods to functionally inhibit PD-2. Each chemical, through its respective target, orchestrates a decrease in PD-2 activity by inhibiting the specific signaling pathways or kinases that are critical for PD-2's function in the cell.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. PD-2 activity is dependent on the cell cycle, and by inhibiting CDK4/6, Palbociclib indirectly inhibits PD-2 by preventing its required cell-cycle progression.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin is an mTOR inhibitor. PD-2 function is associated with mTOR signaling, and inhibition of mTOR can suppress the downstream effects that contribute to the activation and function of PD-2.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 inhibits PI3K, which is upstream of the Akt signaling pathway. Because PD-2 activity is regulated by the PI3K/Akt pathway, LY294002 can indirectly inhibit PD-2 by blocking this pathway.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$104.00
$141.00
14
(1)

Triciribine is an Akt inhibitor. PD-2 is downstream of Akt, and its activity is influenced by Akt signaling. Inhibiting Akt with Triciribine can reduce the functional activity of PD-2.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a MEK inhibitor. MEK is part of the MAPK/ERK pathway which regulates PD-2 activity. Inhibiting MEK with U0126 can lead to decreased PD-2 activity by suppressing ERK signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a p38 MAPK inhibitor. PD-2 is known to be regulated by the p38 MAPK pathway, and by inhibiting this pathway, SB203580 can indirectly inhibit PD-2 activity.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor, and JNK is involved in stress-activated protein kinase signaling that can regulate PD-2. By inhibiting JNK, SP600125 can decrease PD-2 activity.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway that regulates PD-2. Inhibition of MEK by PD98059 can lead to reduced PD-2 activity.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$94.00
$227.00
30
(1)

PP2 is an Src family tyrosine kinase inhibitor. Src kinases can influence PD-2 activity, and by inhibiting these kinases, PP2 can indirectly inhibit PD-2.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

Selumetinib is a MEK inhibitor. By inhibiting MEK, Selumetinib can suppress the MAPK/ERK pathway which is necessary for PD-2 activity, leading to an indirect inhibition of PD-2.